RNA - NASDAQ

Atrium Therapeutics, Inc.

RNA·NASDAQ

$12.17

-1.3%

HealthcareBiotechnology

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$208.18M

EPS-4.4800

P/E Ratio-2.72

Earnings Date09/02/2026

rna

Total Payables

Last Annual Value

4.40M

3-Year CAGR

-2%

5-Year CAGR

-11%

10-Year CAGR

11%

Adjust for Inflation

Atrium Therapeutics, Inc. Competitors Analysis of Total Payables

RNA · NASDAQ

Company	Total Payables	CAGR 3Y	CAGR 5Y	CAGR 10Y
Atrium Therapeutics, Inc. NASDAQ:RNA	4.40M	-20.7%	9.4%	N/A
Caris Life Sciences, Inc. NASDAQ:CAI	39.21M	13.7%	N/A	11.0%
Moderna, Inc. NASDAQ:MRNA	317.00M	-18.4%	-23.1%	27.4%
Nuvalent, Inc. NASDAQ:NUVL	30.16M	48.2%	59.8%	N/A
Jazz Pharmaceuticals plc NASDAQ:JAZZ	178.45M	9.0%	10.2%	20.8%
Rhythm Pharmaceuticals, Inc. NASDAQ:RYTM	13.95M	41.9%	19.4%	22.1%
Cytokinetics, Incorporated NASDAQ:CYTK	105.61M	70.0%	38.0%	37.9%
Bio-Techne Corporation NASDAQ:TECH	36.08M	-4.3%	-1.4%	5.7%
Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL	48.88M	20.3%	18.0%	51.6%

Atrium Therapeutics, Inc. Fair Value Envelope

RNA · NASDAQ

Our analysis suggests that RNA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.17, this represents a potential HIDDEN relative to our calculated worth for Atrium Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $12.17

Related Guides

Blog Categories

Continue your RNA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.